Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Indian J Dermatol Venereol Leprol. 2021 Jan-Feb;87(1):42-48. doi: 10.25259/IJDVL_787_19.
Topical corticosteroids are the standard therapy for the treatment of alopecia areata. Recently, topical latanoprost has been found effective in the treatment of eyelash alopecia areata.
The objective of this study was to compare the efficacy of topical latanoprost ophthalmic solution (group 1) with that of topical betamethasone diproprionate lotion (group 2) in the treatment of localized alopecia areata.
This was a single-centre, randomized, two-armed, parallel-group efficacy trial. Fifty consecutive patients with localized alopecia areata were randomized in a 1:1 ratio to receive either topical latanoprost 0.005% ophthalmic solution or topical betamethasone diproprionate 0.05% lotion. Of these 50 patients, 44 patients (21 in group 1 and 23 in group 2) completed the treatment protocol.
The percentage reduction in area involved with alopecia areata at 16 weeks (primary outcome) was lower in latanoprost vs. betamethasone group (median [interquartile range], 11.1 [0-99.1] vs. 100% [13.6-100], P = 0.02). Significantly lesser patients in the latanoprost group had a complete response to treatment as compared to the betamethasone group (6 [24%] vs. 14 [56%], P = 0.02). The median (interquartile range) hair regrowth score was significantly lower in the latanoprost vs. the betamethasone group (1 [0-4.5] vs. 5 [1-5], P = 0.02). Subjects in the betamethasone group showed a more rapid reduction in the involved area.
Short duration of treatment and follow-up were limitations of this study.
Our results suggest that topical latanoprost 0.005% ophthalmic solution is less effective but safer than topical betamethasone dipropionate 0.05% lotion in the treatment of localized alopecia areata (clinicaltrials.gov: NCT02350023).
局部皮质类固醇是斑秃治疗的标准疗法。最近，局部拉坦前列素已被发现对治疗睫毛斑秃有效。
本研究旨在比较局部拉坦前列素滴眼液（第 1 组）与局部倍他米松二丙酸酯洗剂（第 2 组）治疗局限性斑秃的疗效。
这是一项单中心、随机、双臂、平行组疗效试验。50 例连续局部斑秃患者按 1:1 比例随机分为局部拉坦前列素 0.005%滴眼液或局部倍他米松二丙酸酯 0.05%洗剂组。其中 44 例（第 1 组 21 例，第 2 组 23 例）完成了治疗方案。
16 周时（主要结局）斑秃受累面积减少百分比在拉坦前列素组低于倍他米松组（中位数[四分位间距]，11.1[0-99.1]%比 100%[13.6-100]%，P=0.02）。拉坦前列素组完全缓解的患者明显少于倍他米松组（6[24%]比 14[56%]，P=0.02）。拉坦前列素组的毛发再生评分中位数[四分位间距]明显低于倍他米松组（1[0-4.5]比 5[1-5]，P=0.02）。倍他米松组受累面积减少更快。
本研究的局限性在于治疗和随访时间短。
我们的结果表明，局部拉坦前列素 0.005%滴眼液治疗局限性斑秃的疗效不如局部倍他米松二丙酸酯 0.05%洗剂，但安全性更高（临床试验.gov：NCT02350023）。
